The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gastrointestinal Cancer Drugs Market Research Report 2025
Synopsis
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems.
The global Gastrointestinal Cancer Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Cancer Drugs.
Report Scope
The Gastrointestinal Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastrointestinal Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastrointestinal Cancer Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen & Amgen Ireland
Bristol-Myers Squibb Company
Roche
Eli Lilly and Company
Johnson & Johnson Private
GlaxoSmithKline
Celgene Corporation
Pfizer
Sanofi
Novartis
Segment by Type
Oncology
Radiology
Others
Segment by Application
Hospitals
Specialized Cancer Treatment Centers
Clinics
Ambulatory Surgical Centers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gastrointestinal Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gastrointestinal Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems.
The global Gastrointestinal Cancer Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Cancer Drugs.
Report Scope
The Gastrointestinal Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastrointestinal Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastrointestinal Cancer Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen & Amgen Ireland
Bristol-Myers Squibb Company
Roche
Eli Lilly and Company
Johnson & Johnson Private
GlaxoSmithKline
Celgene Corporation
Pfizer
Sanofi
Novartis
Segment by Type
Oncology
Radiology
Others
Segment by Application
Hospitals
Specialized Cancer Treatment Centers
Clinics
Ambulatory Surgical Centers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gastrointestinal Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gastrointestinal Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Gastrointestinal Cancer Drugs Market Overview
1.1 Product Overview and Scope of Gastrointestinal Cancer Drugs
1.2 Gastrointestinal Cancer Drugs Segment by Type
1.2.1 Global Gastrointestinal Cancer Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Oncology
1.2.3 Radiology
1.2.4 Others
1.3 Gastrointestinal Cancer Drugs Segment by Application
1.3.1 Global Gastrointestinal Cancer Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Specialized Cancer Treatment Centers
1.3.4 Clinics
1.3.5 Ambulatory Surgical Centers
1.4 Global Gastrointestinal Cancer Drugs Market Size Estimates and Forecasts
1.4.1 Global Gastrointestinal Cancer Drugs Revenue 2019-2030
1.4.2 Global Gastrointestinal Cancer Drugs Sales 2019-2030
1.4.3 Global Gastrointestinal Cancer Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Gastrointestinal Cancer Drugs Market Competition by Manufacturers
2.1 Global Gastrointestinal Cancer Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Gastrointestinal Cancer Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Gastrointestinal Cancer Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Gastrointestinal Cancer Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Gastrointestinal Cancer Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gastrointestinal Cancer Drugs, Product Type & Application
2.7 Gastrointestinal Cancer Drugs Market Competitive Situation and Trends
2.7.1 Gastrointestinal Cancer Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gastrointestinal Cancer Drugs Players Market Share by Revenue
2.7.3 Global Gastrointestinal Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gastrointestinal Cancer Drugs Retrospective Market Scenario by Region
3.1 Global Gastrointestinal Cancer Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Gastrointestinal Cancer Drugs Global Gastrointestinal Cancer Drugs Sales by Region: 2019-2030
3.2.1 Global Gastrointestinal Cancer Drugs Sales by Region: 2019-2024
3.2.2 Global Gastrointestinal Cancer Drugs Sales by Region: 2025-2030
3.3 Global Gastrointestinal Cancer Drugs Global Gastrointestinal Cancer Drugs Revenue by Region: 2019-2030
3.3.1 Global Gastrointestinal Cancer Drugs Revenue by Region: 2019-2024
3.3.2 Global Gastrointestinal Cancer Drugs Revenue by Region: 2025-2030
3.4 North America Gastrointestinal Cancer Drugs Market Facts & Figures by Country
3.4.1 North America Gastrointestinal Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Gastrointestinal Cancer Drugs Sales by Country (2019-2030)
3.4.3 North America Gastrointestinal Cancer Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Gastrointestinal Cancer Drugs Market Facts & Figures by Country
3.5.1 Europe Gastrointestinal Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Gastrointestinal Cancer Drugs Sales by Country (2019-2030)
3.5.3 Europe Gastrointestinal Cancer Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gastrointestinal Cancer Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Gastrointestinal Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Gastrointestinal Cancer Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Gastrointestinal Cancer Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Gastrointestinal Cancer Drugs Market Facts & Figures by Country
3.7.1 Latin America Gastrointestinal Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Gastrointestinal Cancer Drugs Sales by Country (2019-2030)
3.7.3 Latin America Gastrointestinal Cancer Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Gastrointestinal Cancer Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Gastrointestinal Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Gastrointestinal Cancer Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Gastrointestinal Cancer Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Gastrointestinal Cancer Drugs Sales by Type (2019-2030)
4.1.1 Global Gastrointestinal Cancer Drugs Sales by Type (2019-2024)
4.1.2 Global Gastrointestinal Cancer Drugs Sales by Type (2025-2030)
4.1.3 Global Gastrointestinal Cancer Drugs Sales Market Share by Type (2019-2030)
4.2 Global Gastrointestinal Cancer Drugs Revenue by Type (2019-2030)
4.2.1 Global Gastrointestinal Cancer Drugs Revenue by Type (2019-2024)
4.2.2 Global Gastrointestinal Cancer Drugs Revenue by Type (2025-2030)
4.2.3 Global Gastrointestinal Cancer Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Gastrointestinal Cancer Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Gastrointestinal Cancer Drugs Sales by Application (2019-2030)
5.1.1 Global Gastrointestinal Cancer Drugs Sales by Application (2019-2024)
5.1.2 Global Gastrointestinal Cancer Drugs Sales by Application (2025-2030)
5.1.3 Global Gastrointestinal Cancer Drugs Sales Market Share by Application (2019-2030)
5.2 Global Gastrointestinal Cancer Drugs Revenue by Application (2019-2030)
5.2.1 Global Gastrointestinal Cancer Drugs Revenue by Application (2019-2024)
5.2.2 Global Gastrointestinal Cancer Drugs Revenue by Application (2025-2030)
5.2.3 Global Gastrointestinal Cancer Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Gastrointestinal Cancer Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen & Amgen Ireland
6.1.1 Amgen & Amgen Ireland Corporation Information
6.1.2 Amgen & Amgen Ireland Description and Business Overview
6.1.3 Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Product Portfolio
6.1.5 Amgen & Amgen Ireland Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Corporation Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Gastrointestinal Cancer Drugs Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Eli Lilly and Company
6.4.1 Eli Lilly and Company Corporation Information
6.4.2 Eli Lilly and Company Description and Business Overview
6.4.3 Eli Lilly and Company Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Eli Lilly and Company Gastrointestinal Cancer Drugs Product Portfolio
6.4.5 Eli Lilly and Company Recent Developments/Updates
6.5 Johnson & Johnson Private
6.5.1 Johnson & Johnson Private Corporation Information
6.5.2 Johnson & Johnson Private Description and Business Overview
6.5.3 Johnson & Johnson Private Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Johnson & Johnson Private Gastrointestinal Cancer Drugs Product Portfolio
6.5.5 Johnson & Johnson Private Recent Developments/Updates
6.6 GlaxoSmithKline
6.6.1 GlaxoSmithKline Corporation Information
6.6.2 GlaxoSmithKline Description and Business Overview
6.6.3 GlaxoSmithKline Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GlaxoSmithKline Gastrointestinal Cancer Drugs Product Portfolio
6.6.5 GlaxoSmithKline Recent Developments/Updates
6.7 Celgene Corporation
6.6.1 Celgene Corporation Corporation Information
6.6.2 Celgene Corporation Description and Business Overview
6.6.3 Celgene Corporation Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Celgene Corporation Gastrointestinal Cancer Drugs Product Portfolio
6.7.5 Celgene Corporation Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Corporation Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Pfizer Gastrointestinal Cancer Drugs Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Corporation Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sanofi Gastrointestinal Cancer Drugs Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Gastrointestinal Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis Gastrointestinal Cancer Drugs Product Portfolio
6.10.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gastrointestinal Cancer Drugs Industry Chain Analysis
7.2 Gastrointestinal Cancer Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gastrointestinal Cancer Drugs Production Mode & Process
7.4 Gastrointestinal Cancer Drugs Sales and Marketing
7.4.1 Gastrointestinal Cancer Drugs Sales Channels
7.4.2 Gastrointestinal Cancer Drugs Distributors
7.5 Gastrointestinal Cancer Drugs Customers
8 Gastrointestinal Cancer Drugs Market Dynamics
8.1 Gastrointestinal Cancer Drugs Industry Trends
8.2 Gastrointestinal Cancer Drugs Market Drivers
8.3 Gastrointestinal Cancer Drugs Market Challenges
8.4 Gastrointestinal Cancer Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Gastrointestinal Cancer Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Gastrointestinal Cancer Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Gastrointestinal Cancer Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Gastrointestinal Cancer Drugs Sales (g) of Key Manufacturers (2019-2024)
Table 5. Global Gastrointestinal Cancer Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Gastrointestinal Cancer Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Gastrointestinal Cancer Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Gastrointestinal Cancer Drugs Average Price (USD/g) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Gastrointestinal Cancer Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Gastrointestinal Cancer Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Gastrointestinal Cancer Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Gastrointestinal Cancer Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Gastrointestinal Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Cancer Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Gastrointestinal Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Gastrointestinal Cancer Drugs Sales by Region (2019-2024) & (g)
Table 18. Global Gastrointestinal Cancer Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Gastrointestinal Cancer Drugs Sales by Region (2025-2030) & (g)
Table 20. Global Gastrointestinal Cancer Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Gastrointestinal Cancer Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Gastrointestinal Cancer Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Gastrointestinal Cancer Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Gastrointestinal Cancer Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Gastrointestinal Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Gastrointestinal Cancer Drugs Sales by Country (2019-2024) & (g)
Table 27. North America Gastrointestinal Cancer Drugs Sales by Country (2025-2030) & (g)
Table 28. North America Gastrointestinal Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Gastrointestinal Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Gastrointestinal Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Gastrointestinal Cancer Drugs Sales by Country (2019-2024) & (g)
Table 32. Europe Gastrointestinal Cancer Drugs Sales by Country (2025-2030) & (g)
Table 33. Europe Gastrointestinal Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Gastrointestinal Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Gastrointestinal Cancer Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Gastrointestinal Cancer Drugs Sales by Region (2019-2024) & (g)
Table 37. Asia Pacific Gastrointestinal Cancer Drugs Sales by Region (2025-2030) & (g)
Table 38. Asia Pacific Gastrointestinal Cancer Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Gastrointestinal Cancer Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Gastrointestinal Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Gastrointestinal Cancer Drugs Sales by Country (2019-2024) & (g)
Table 42. Latin America Gastrointestinal Cancer Drugs Sales by Country (2025-2030) & (g)
Table 43. Latin America Gastrointestinal Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Gastrointestinal Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Gastrointestinal Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Gastrointestinal Cancer Drugs Sales by Country (2019-2024) & (g)
Table 47. Middle East & Africa Gastrointestinal Cancer Drugs Sales by Country (2025-2030) & (g)
Table 48. Middle East & Africa Gastrointestinal Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Gastrointestinal Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Gastrointestinal Cancer Drugs Sales (g) by Type (2019-2024)
Table 51. Global Gastrointestinal Cancer Drugs Sales (g) by Type (2025-2030)
Table 52. Global Gastrointestinal Cancer Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Gastrointestinal Cancer Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Gastrointestinal Cancer Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Gastrointestinal Cancer Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Gastrointestinal Cancer Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Gastrointestinal Cancer Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Gastrointestinal Cancer Drugs Price (USD/g) by Type (2019-2024)
Table 59. Global Gastrointestinal Cancer Drugs Price (USD/g) by Type (2025-2030)
Table 60. Global Gastrointestinal Cancer Drugs Sales (g) by Application (2019-2024)
Table 61. Global Gastrointestinal Cancer Drugs Sales (g) by Application (2025-2030)
Table 62. Global Gastrointestinal Cancer Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Gastrointestinal Cancer Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Gastrointestinal Cancer Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Gastrointestinal Cancer Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Gastrointestinal Cancer Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Gastrointestinal Cancer Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Gastrointestinal Cancer Drugs Price (USD/g) by Application (2019-2024)
Table 69. Global Gastrointestinal Cancer Drugs Price (USD/g) by Application (2025-2030)
Table 70. Amgen & Amgen Ireland Corporation Information
Table 71. Amgen & Amgen Ireland Description and Business Overview
Table 72. Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 73. Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Product
Table 74. Amgen & Amgen Ireland Recent Developments/Updates
Table 75. Bristol-Myers Squibb Company Corporation Information
Table 76. Bristol-Myers Squibb Company Description and Business Overview
Table 77. Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 78. Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Product
Table 79. Bristol-Myers Squibb Company Recent Developments/Updates
Table 80. Roche Corporation Information
Table 81. Roche Description and Business Overview
Table 82. Roche Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 83. Roche Gastrointestinal Cancer Drugs Product
Table 84. Roche Recent Developments/Updates
Table 85. Eli Lilly and Company Corporation Information
Table 86. Eli Lilly and Company Description and Business Overview
Table 87. Eli Lilly and Company Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 88. Eli Lilly and Company Gastrointestinal Cancer Drugs Product
Table 89. Eli Lilly and Company Recent Developments/Updates
Table 90. Johnson & Johnson Private Corporation Information
Table 91. Johnson & Johnson Private Description and Business Overview
Table 92. Johnson & Johnson Private Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 93. Johnson & Johnson Private Gastrointestinal Cancer Drugs Product
Table 94. Johnson & Johnson Private Recent Developments/Updates
Table 95. GlaxoSmithKline Corporation Information
Table 96. GlaxoSmithKline Description and Business Overview
Table 97. GlaxoSmithKline Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 98. GlaxoSmithKline Gastrointestinal Cancer Drugs Product
Table 99. GlaxoSmithKline Recent Developments/Updates
Table 100. Celgene Corporation Corporation Information
Table 101. Celgene Corporation Description and Business Overview
Table 102. Celgene Corporation Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 103. Celgene Corporation Gastrointestinal Cancer Drugs Product
Table 104. Celgene Corporation Recent Developments/Updates
Table 105. Pfizer Corporation Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 108. Pfizer Gastrointestinal Cancer Drugs Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Sanofi Corporation Information
Table 111. Sanofi Description and Business Overview
Table 112. Sanofi Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 113. Sanofi Gastrointestinal Cancer Drugs Product
Table 114. Sanofi Recent Developments/Updates
Table 115. Novartis Corporation Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Gastrointestinal Cancer Drugs Sales (g), Revenue (US$ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 118. Novartis Gastrointestinal Cancer Drugs Product
Table 119. Novartis Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Gastrointestinal Cancer Drugs Distributors List
Table 123. Gastrointestinal Cancer Drugs Customers List
Table 124. Gastrointestinal Cancer Drugs Market Trends
Table 125. Gastrointestinal Cancer Drugs Market Drivers
Table 126. Gastrointestinal Cancer Drugs Market Challenges
Table 127. Gastrointestinal Cancer Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Gastrointestinal Cancer Drugs
Figure 2. Global Gastrointestinal Cancer Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Gastrointestinal Cancer Drugs Market Share by Type in 2023 & 2030
Figure 4. Oncology Product Picture
Figure 5. Radiology Product Picture
Figure 6. Others Product Picture
Figure 7. Global Gastrointestinal Cancer Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Gastrointestinal Cancer Drugs Market Share by Application in 2023 & 2030
Figure 9. Hospitals
Figure 10. Specialized Cancer Treatment Centers
Figure 11. Clinics
Figure 12. Ambulatory Surgical Centers
Figure 13. Global Gastrointestinal Cancer Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Gastrointestinal Cancer Drugs Market Size (2019-2030) & (US$ Million)
Figure 15. Global Gastrointestinal Cancer Drugs Sales (2019-2030) & (g)
Figure 16. Global Gastrointestinal Cancer Drugs Average Price (USD/g) & (2019-2030)
Figure 17. Gastrointestinal Cancer Drugs Report Years Considered
Figure 18. Gastrointestinal Cancer Drugs Sales Share by Manufacturers in 2023
Figure 19. Global Gastrointestinal Cancer Drugs Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Gastrointestinal Cancer Drugs Players: Market Share by Revenue in 2023
Figure 21. Gastrointestinal Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Gastrointestinal Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Gastrointestinal Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 24. North America Gastrointestinal Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 25. U.S. Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Gastrointestinal Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 28. Europe Gastrointestinal Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 29. Germany Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Gastrointestinal Cancer Drugs Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Gastrointestinal Cancer Drugs Revenue Market Share by Region (2019-2030)
Figure 36. China Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Taiwan Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Philippines Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Gastrointestinal Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 47. Latin America Gastrointestinal Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Gastrointestinal Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Gastrointestinal Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. U.A.E Gastrointestinal Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Gastrointestinal Cancer Drugs by Type (2019-2030)
Figure 57. Global Revenue Market Share of Gastrointestinal Cancer Drugs by Type (2019-2030)
Figure 58. Global Gastrointestinal Cancer Drugs Price (USD/g) by Type (2019-2030)
Figure 59. Global Sales Market Share of Gastrointestinal Cancer Drugs by Application (2019-2030)
Figure 60. Global Revenue Market Share of Gastrointestinal Cancer Drugs by Application (2019-2030)
Figure 61. Global Gastrointestinal Cancer Drugs Price (USD/g) by Application (2019-2030)
Figure 62. Gastrointestinal Cancer Drugs Value Chain
Figure 63. Gastrointestinal Cancer Drugs Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
